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Permanent Pacemaker Implantation After
Transcatheter Aortic Valve Replacement
The PARTNER (Placement of AoRtic TraNscathetER Valves)
Trial and RegistryTamim M. Nazif, MD,* José M. Dizon, MD,* Rebecca T. Hahn, MD,* Ke Xu, PHD,y Vasilis Babaliaros, MD,z
Pamela S. Douglas, MD,x Mikhael F. El-Chami, MD,z Howard C. Herrmann, MD,k Michael Mack, MD,{
Raj R. Makkar, MD,# D. Craig Miller, MD,** Augusto Pichard, MD,yy E. Murat Tuzcu, MD,zz Wilson Y. Szeto, MD,k
John G. Webb, MD,xx Jeffrey W. Moses, MD,* Craig R. Smith, MD,* Mathew R. Williams, MD,* Martin B. Leon, MD,*
Susheel K. Kodali, MD,* for the PARTNER Publications OfﬁceABSTRACTOBJECTIVES The purpose of this study was to identify predictors and clinical implications of permanent pacemaker
(PPM) implantation after transcatheter aortic valve replacement (TAVR).
BACKGROUND Cardiac conduction disturbances requiring PPM are a frequent complication of TAVR. However, limited
data is available regarding this complication after TAVR with a balloon-expandable valve.
METHODS The study included patients without prior pacemaker who underwent TAVR in the PARTNER (Placement of
AoRtic TraNscathetER Valves) trial and registry and investigated predictors and clinical effect of new PPM.
RESULTS Of 2,559 TAVR patients, 586 were excluded due to pre-existing PPM. A new PPM was required in 173 of the
remaining 1,973 patients (8.8%). By multivariable analysis, predictors of PPM included right bundle branch block (odds
ratio [OR]: 7.03, 95% conﬁdence interval [CI]: 4.92 to 10.06, p < 0.001), prosthesis diameter/left ventricular (LV)
outﬂow tract diameter (for each 0.1 increment, OR: 1.29, 95% CI: 1.10 to 1.51, p ¼ 0.002), LV end-diastolic diameter (for
each 1 cm, OR: 0.68, 95% CI: 0.53 to 0.87, p ¼ 0.003), and treatment in continued access registry (OR: 1.77, 95% CI:
1.08 to 2.92, p ¼ 0.025). Patients requiring PPM had a longer mean duration of post-procedure hospitalization (7.3  2.7
days vs. 6.2  2.8 days, p ¼ 0.001). At 1 year, new PPM was associated with signiﬁcantly higher repeat hospitalization
(23.9% vs. 18.2%, p ¼ 0.05) and mortality or repeat hospitalization (42.0% vs. 32.6%, p ¼ 0.007). There was no dif-
ference between groups in LV ejection fraction at 1 year.
CONCLUSIONS PPM was required in 8.8% of patients without prior PPM who underwent TAVR with a balloon-
expandable valve in the PARTNER trial and registry. In addition to pre-existing right bundle branch block, the
prosthesis to LV outﬂow tract diameter ratio and the LV end-diastolic diameter were identiﬁed as novel predictors of
PPM after TAVR. New PPM was associated with a longer duration of hospitalization and higher rates of repeat
hospitalization and mortality or repeat hospitalization at 1 year. (THE PARTNER TRIAL: Placement of AoRtic
TraNscathetER Valves Trial; NCT00530894) (J Am Coll Cardiol Intv 2015;8:60–9) © 2015 by the American College
of Cardiology Foundation.
AB BR E V I A T I O N S
AND ACRONYM S
AS = aortic stenosis
CEC = clinical events
committee
ECG = electrocardiogram
ESV = Edwards SAPIEN Valve
LVEDd = left ventricular end-
diastolic diameter
LVEF = left ventricular
ejection fraction
MCV = Medtronic CoreValve
PPM = permanent pacemaker
RBBB = right bundle branch
block
TAVR = transcatheter aortic
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61T he PARTNER (Placement of Aortic Transcath-eter Valve) trial established transcatheteraortic valve replacement (TAVR) as a thera-
peutic alternative for inoperable and high-risk surgical
candidates with symptomatic, severe aortic stenosis
(AS) (1,2). Cardiac conduction disturbances requiring
permanent pacemaker implantation (PPM) are a
frequent complication of TAVR. The exact frequency
of new PPM varies based on the valve system used
and is signiﬁcantly lower with the balloon-
expandable Edwards SAPIEN valve (ESV) (Edwards
Lifesciences, Irvine, California) than the self-
expanding Medtronic CoreValve (MCV) (Medtronic,
Minneapolis, Minnesota). Recent meta-analyses
report average PPM rates ranging from 5.9% to 6.5%
for ESV and from 24.5% to 25.8% for MCV (3–5).SEE PAGE 70
valve replacementLimited data are available regarding predictors and
clinical implications of PPM after TAVR, particularly
with respect to ESV. Furthermore, existing studies
generally lack core laboratory analysis of diagnostic
studies and independent adjudication of important
adverse outcomes. The purpose of the current study
was to determine the incidence, predictors, and
clinical effect of PPM following TAVR with ESV in a
large population of patients with core laboratory and
clinical events committee (CEC)–adjudicated data
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STUDY POPULATION AND DESIGN. The
design and results of the PARTNER trial have
been previously described (1,2). In the ran-
domized trial, inoperable and high-risk sur-
gical candidates with symptomatic, severe AS
underwent TAVR with a 23- or 26-mm ESV by
the transfemoral or transapical (high-risk
patients only) approach. Following comple-
tion of enrollment in the randomized trial,
additional patients underwent TAVR in a
continued access registry, which utilized
the same inclusion and exclusion criteria,
screening committee, core laboratories, and
CEC. The current analysis utilized an as-
treated population of patients who under-
went TAVR in the randomized trial and
registry and excluded those with prior PPM. The rate
of new PPM after TAVR was determined, and pre-
dictors were identiﬁed by univariate and multi-
variable analysis. Clinical and echocardiographic
outcomes were compared between patients with and
without new PPM.
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62electrocardiograms (ECGs), and transthoracic echo-
cardiograms were obtained at baseline, hospital
discharge/7 days, 30 days, 6 months, and 1 year. All
ECGs and echocardiograms were interpreted by in-
dependent core laboratories using methodology pre-
viously described (6). Of note, left ventricular outﬂow
tract (LVOT) diameter was measured in midsystole,
no more than 0.5 cm apical to the annular measure-
ment, and in a location avoiding a septal bulge,
dystrophic calciﬁcation, or systolic anterior motion of
the mitral leaﬂets. Pacemaker type and indication
were extracted from operative reports and clinical
notes. The indications were classiﬁed into the
following categories: advanced atrioventricular block
(complete and high-degree atrioventricular block),
second-degree heart block (Mobitz 2 and Mobitz 1
with additional conduction disturbance), sick sinus
syndrome (including tachycardia-bradycardia syn-
drome), and other bradycardia.
STATISTICAL ANALYSIS. Results are presented as
means  SD or counts and percentages. Continuous
variables were compared with the Wilcoxon rank sum
test, and categorical variables were compared with
the chi-square or Fisher exact test. To identify inde-
pendent predictors of PPM, multivariable logistic
regression was performed with entry and stay criteria
of 0.1 and 0.1. Candidate variables for the multivari-
able model were required to have clinical relevance
and a p value <0.15 in the univariate analysis, which
included all available baseline clinical, echocardio-
graphic, ECG, and procedural data. Outcomes at
30 days and 1 year were analyzed with Kaplan-Meierf Pacemaker Implantation
ys the post-procedure day of pacemaker implantation in all cases.estimates and compared between groups with the
log-rank test. For all tests, a 2-sided alpha value <0.05
was required for statistical signiﬁcance. Statistical
analyses were performed using SAS software, version
9.2 (SAS Institute Inc., Cary, North Carolina). Data
extraction was performed on July 19, 2013.
RESULTS
PATIENT POPULATION AND BASELINE CHARACTERISTICS.
A total of 2,559 patients underwent TAVR in the
PARTNER trial and registry. Of these, 586 were
excluded from the current analysis due to prior PPM,
resulting in a ﬁnal study population of 1,973 patients
from the randomized trial (n ¼ 409) and continued
access registry (n ¼ 1,564). PPM was required within
30 days of TAVR in 173 patients (8.8% of those
without prior PPM and 6.8% of total population). The
rate of PPM implantation was higher in the continued
access registry than the randomized trial (9.6% vs.
5.6% of those without prior pacemaker). The mean
time to PPM after TAVR was 4.1  4.3 days, and the
median was 3 days (interquartile range: 1 to 6 days)
(Figure 1). In the vast majority of cases, PPM was
performed during the index hospitalization (97.1%)
and within 7 days of the procedure (86.1%).
The most common indication for PPM was high-
degree or complete atrioventricular block (79%),
followed by sick sinus syndrome (17.3%) (Figure 2A).
The vast majority of devices were either dual-
chamber (n ¼ 131, 75.7%) or single-chamber (n ¼ 34,
19.7%) right ventricular pacemakers, and very few
were biventricular pacemakers (n ¼ 5, 2.9%), im-
plantable cardioverter-deﬁbrillators (n ¼ 1, 0.6%), or
biventricular pacemaker–implantable cardioverter-
deﬁbrillators (n ¼ 1, 0.6%) (Figure 2B). Among
patients not requiring PPM within 30 days, only an
additional 29 (1.9%) received PPM within 1 year, and
there was no signiﬁcant difference in this rate
between patients treated in the trial or registry (1.5%
vs. 2.0%, p ¼ 0.57).
Baseline patient characteristics are shown, strati-
ﬁed by requirement for PPM, in Table 1. Overall, pa-
tients were elderly (mean age 84.3  7.2 years), with a
high burden of medical comorbidities. The patients
were at high surgical risk, as reﬂected by Society of
Thoracic Surgeons score (11.3  4.0) and logistic
EuroSCORE (25.5  15.9). The groups were similar
with respect to baseline clinical characteristics, with
the exception of more frequent prior chest wall radi-
ation (5.2% vs. 2.3%, p ¼ 0.04) in the PPM group.
BASELINE ECG AND ECHOCARDIOGRAPHIC
CHARACTERISTICS. Core laboratory analysis of a
baseline ECG was available in 1,948 patients (98.7%),
FIGURE 2 Pacemaker Indication and Device Type
(A) The indication for permanent pacemaker after transcatheter
aortic valve replacement is displayed: advanced atrioventricular
block (AVB); second-degree heart block (2nd Deg); sick sinus
syndrome (SSS); and other bradycardia (Other). (B) The ﬁgure
displays the type of pacemaker device implanted, including: dual
chamber right ventricular pacemaker (Dual); single chamber right
ventricular pacemaker (Single); biventricular pacemaker (Bi-V);
and implantable cardioverter-deﬁbrillator (ICD).
TABLE 1 Baseline Characteristics
New PPM
(n ¼ 173)
No PPM
(n ¼ 1,800) p Value
Age, yrs 84.8  7.2 84.2  7.2 0.33
Male 46.2 48.6 0.55
STS score 11.5  4.1 11.3  4.0 0.15
Logistic EuroSCORE 26.0  17.3 25.4  15.8 (1,001) 0.95
Frailty 13.0 13.0 1.00
NYHA functional class
III 59.0 47.8 0.005
IV 31.2 47.4 <0.001
CAD 80.9 75.8 0.13
Prior MI 25.6 25.2 0.92
Prior PCI 40.1 37.7 0.53
Prior CABG 42.2 40.3 0.63
Prior BAV 22.8 21.4 0.67
Arrhythmia 48.6 42.2 0.11
PVD 41.4 43.4 0.63
Porcelain aorta 4.0 4.0 0.98
CVD 20.0 26.7 0.06
Hypertension 89.6 91.9 0.30
Dyslipidemia 84.4 83.0 0.65
Diabetes mellitus 35.8 36.3 0.90
Renal disease (cr $2) 16.8 16.2 0.86
Liver disease 2.9 2.8 0.81
COPD 48.0 45.9 0.61
Oxygen dependent 9.8 12.4 0.32
Pulmonary hypertension 39.4 37.9 0.69
Chest wall radiation 5.2 2.3 0.04
Values are mean  SD or %.
BAV ¼ balloon aortic valvuloplasty; CAD ¼ coronary artery disease;
cr ¼ creatinine; COPD ¼ chronic obstructive pulmonary disease; CVD ¼ cerebro-
vascular disease; EuroSCORE ¼ European System for Cardiac Operative Risk
Evaluation; MI ¼ myocardial infarction; NYHA ¼ New York Heart Association;
PCI ¼ percutaneous coronary intervention; PPM ¼ permanent pacemaker;
PVD ¼ peripheral vascular disease; STS ¼ Society of Thoracic Surgeons.
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63and an echocardiogram in 1,936 patients (98.1%). ECG
and echocardiographic characteristics of patients
with and without new PPM are shown in Table 2.
Patients who required PPM were more likely to have
baseline ECG ﬁndings of bradycardia (sinus brady-
cardia, sinus pauses, or junctional bradycardia)
(4.1% vs. 1.5%, p ¼ 0.02), right bundle branch block
(RBBB) (47.6% vs. 12.8%, p < 0.001), and left anterior
fascicular block (16.5% vs. 8.5%, p < 0.009). By
analysis of baseline echocardiograms, the PPM group
also had smaller left ventricular end-diastolic diam-
eter (LVEDd) (4.32  0.71 cm vs. 4.47  0.74 cm,
p ¼ 0.02) and LVOT diameter (1.98  0.18 cm vs. 2.01
 0.18 cm, p ¼ 0.02), and larger ratio of annulus
diameter to LVOT diameter (1.09  0.11 vs. 1.07 
0.10, p ¼ 0.004). There were no signiﬁcantdifferences between groups with respect to other
important echocardiographic variables, including
transvalvular peak and mean velocities, aortic valve
area, annulus diameter, left ventricular ejection
fraction (LVEF), and indexes of hypertrophy.
PROCEDURAL CHARACTERISTICS. Procedural vari-
ables are displayed, stratiﬁed by PPM requirement, in
Table 3. Among patients who required PPM, there
were numerically higher rates of transapical access
(48.0% vs. 42.1%, p ¼ 0.13) and use of the 26-mm
(as opposed to 23-mm) prosthesis (51.2% vs. 44.3%,
p ¼ 0.09). The ratio of prosthesis diameter to LVOT
diameter (valve/LVOT) was signiﬁcantly greater (1.23
 0.11 vs. 1.21  0.11, p ¼ 0.001) in patients who
required PPM. There were no signiﬁcant differences
in the rate of balloon valvuloplasty, rate of post-
dilation, and post-dilation balloon size, but patients
who required PPM were signiﬁcantly more likely to
require intra-aortic balloon pump support (7.0% vs.
TABLE 2 Baseline ECG and Echocardiographic Characteristics
New PPM
(n ¼ 173)
No PPM
(n ¼ 1,800) p Value
Electrocardiographic characteristics
Sinus rhythm 73.7 73.8 0.97
Atrial tachyarrhythmia* 22.8 23.6 0.82
Bradycardia† 4.1 1.5 0.02
First-degree AVB 18.8 14.4 0.12
Intraventricular conduction
disturbance:
RBBB 47.6 12.8 <0.001
Incomplete RBBB 2.2 1.9 0.70
LBBB 7.1 9.0 0.39
Left anterior hemiblock 16.5 8.5 0.009
Left posterior hemiblock 0.0 0.1 1.00
IVCD 3.3 7.4 0.14
Echocardiographic characteristics
AV peak velocity, m/s 4.21  0.60 4.23  0.64 0.52
AV mean gradient, mm Hg 45.20  13.54 45.54  14.49 0.36
Aortic valve area, cm2 0.63  0.19 0.65  0.19 0.35
Aortic valve annulus, cm 1.88  0.27 1.90  0.27 0.58
LVOT diameter, cm 1.98  0.18 2.01  0.18 0.02
Annulus/LVOT 1.09  0.11 1.07  0.10 0.004
LV mass, g 240.1  78.4 247.0  75.2 0.35
IVSd diameter, cm 1.62  0.35 1.60  0.33 0.61
LVOT/IVSd (n) 1.09  0.30 (98) 1.31  0.30 (892) 0.34
LVED diameter, cm 4.32  0.71 4.47  0.74 0.02
LVEF 53.5 53.9 0.67
Values are % or mean  SD. *Atrial ﬁbrillation, atrial ﬂutter, or atrial tachycardia. †Sinus
bradycardia, sinus pauses, or junctional bradycardia.
AV ¼ aortic valve; AVB ¼ atrioventricular block; ECG ¼ electrocardiogram; IVSd ¼ interven-
tricular septum diastolic diameter; LBBB ¼ left bundle branch block; LV¼ left ventricular; LVED¼
left ventricular end-diastolic; LVEF ¼ left ventricular ejection fraction; LVOT ¼ left ventricular
outﬂow tract; PPM ¼ permanent pacemaker; RBBB ¼ right bundle branch block.
TABLE 3 Procedural Characteristics
New PPM
(n ¼ 173)
No PPM
(n ¼ 1,800) p Value
Access route
Transfemoral 52.0 57.9 0.13
Transapical 48.0 42.1 0.13
Prosthesis size
23 mm 48.8 55.7 0.09
26 mm 51.2 44.3 0.09
Prosthesis d./annulus d. 1.15  0.08 1.14  0.07 0.40
Prosthesis d./LVOT d. 1.25  0.11 1.22  0.10 <0.001
Post-dilation 9.3 10.6 0.60
Post-dilation balloon size 22.7  2.8 23.0  2.6 0.69
Hemodynamic support
Cardiopulmonary bypass 5.8 5.0 0.63
Intra-aortic balloon pump 7.0 3.2 0.01
Conversion to open surgery 0 1.6 0.17
Time to discharge post-TAVR, days 7.3  2.7 6.2  2.8 <0.001
Values are % or mean  SD.
d. ¼ diameter; other abbreviations as in Table 2.
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643.2%, p ¼ 0.01). Following the procedure, the PPM
group had a longer mean duration of hospitalization
(7.3  2.7 days vs. 6.2  2.8 days, p ¼ 0.001).
MULTIVARIABLE ANALYSIS. The candidate variables
for the multivariable logistic regression analysis for
predictors of PPM are shown in Table 4. Independent
predictors of PPM included RBBB (odds ratio [OR]:
7.03, 95% conﬁdence interval [CI]: 4.92 to 10.06,
p < 0.001), valve/LVOT (OR: 1.29 per 0.1 increment,
95% CI: 1.10 to 1.51, p ¼ 0.002), LVEDd (OR: 0.68 per
1-cm increment, 95% CI: 0.53 to 0.87, p ¼ 0.003), and
treatment in the continued access registry (OR: 1.77,
95% CI: 1.08 to 2.92, p ¼ 0.025).
CLINICAL OUTCOMES. Clinical outcomes at 30 days
and 1 year are presented in Table 5. At 30 days, new
PPM was associated with a signiﬁcantly higher rate of
repeat hospitalization (10.6% vs 5.9%, p ¼ 0.02), but
not with mortality (7.5% vs. 5.8%, p ¼ 0.40). Simi-
larly, at 1 year, new PPM was not associated with
signiﬁcantly higher all-cause mortality (26.3% vs.20.8%, p ¼ 0.08), but was associated with signiﬁ-
cantly higher repeat hospitalization (23.9% vs. 18.2%,
p ¼ 0.05) and mortality or repeat hospitalization
(42.0% vs. 32.6%, p ¼ 0.007) (Figure 3). There were no
signiﬁcant differences between groups in heart fail-
ure symptoms and functional status as assessed by
New York Heart Association functional class and 6-
min walk time.
ECG AND ECHOCARDIOGRAPHIC OUTCOMES. Core
laboratory ECG analysis was available for 97.9% of
surviving patients at hospital discharge, 92.6% at
30 days, 86.0% at 6 months, and 82.5% at 1 year. ECG
analysis revealed ventricular pacing in the new PPM
group in 47.3% of patients at discharge/7 days,
50.7% at 30 days, 47.1% at 6 months, and 50.5% at 1
year. Echocardiograms were analyzed by the core
laboratory for 100% of surviving patients at hospital
discharge, 92.8% at 30 days, 86.3% at 6 months, and
78.7% at 1 year. The LVEF was similar between groups
at baseline (53.5% vs. 53.9%, p ¼ 0.67) and 1 year
(55.4% vs. 56.8%, p ¼ 0.18) (Figure 4). Left ventricular
dimensions, including LVEDd and left ventricular
(LV) end-systolic diameter, were also similar at 1 year.
DISCUSSION
This report of 1,973 patients without prior pacemaker
from the PARTNER trial and registry is the largest
existing study to analyze the incidence, predictors,
and clinical effect of PPM after TAVR. It is particularly
notable for CEC adjudication of important clinical
TABLE 4 Univariate and Signiﬁcant Multivariable Predictors of PPM after TAVR
Univariate
p Value
Multivariable
p Value
Odds Ratio
(95% CI)
Odds Ratio
(95% CI)
Continued access registry 1.78 (1.13–2.80) 0.013 1.77 (1.08–2.92) 0.025
Demographics
Age >80 yrs 1.36 (0.90–2.05) 0.140
CAD 1.36 (0.92–2.01) 0.128
Arrhythmia 1.29 (0.95–1.77) 0.106
Chest wall radiation 2.29 (1.10–4.79) 0.028
Electrocardiographic
Bradycardia 2.88 (1.23–6.73) 0.015
First-degree AVB 1.38 (0.92–2.07) 0.121
RBBB 6.23 (4.47–8.68) <0.001 7.03 (4.92–10.06) <0.001
Left anterior hemiblock 2.58 (1.65–4.02) <0.001
Echocardiographic
LVED diameter
(per 1-cm increment)
0.76 (0.61–0.95) 0.018 0.68 (0.53–0.87) 0.003
LVOT diameter 0.37 (0.15–0.87) 0.024
Procedural
Transapical access 1.27 (0.93–1.74) 0.133
23 mm vs. 26 mm prosthesis 0.76 (0.55–1.04) 0.086
Prosthesis d./LVOT d.
(per 0.1 increment)
1.31 (1.13–1.51) <0.001 1.29 (1.10–1.51) 0.002
CI ¼ conﬁdence interval; other abbreviations as in Tables 1 to 3.
TABLE 5 Multivariable Logistic Regression Analysis for
Predictors of PPM—Clinical Outcomes
New PPM
(n ¼ 173)
No PPM
(n ¼ 1,800) p Value
30-Day Outcomes
Mortality
From any cause 7.5 5.8 0.40
From cardiovascular cause 3.6 4.4 0.57
Repeat hospitalization 10.6 5.9 0.02
Stroke 3.5 3.9 0.78
Myocardial infarction 0.6 1.0 0.58
Major vascular complication 6.9 7.6 0.77
Hemorrhagic event 7.6 11.5 0.12
Major bleeding 5.2 9.4 0.07
Minor bleeding 2.3 2.2 0.92
Renal failure requiring dialysis 5.4 2.4 0.03
1-Year Outcomes
Mortality
From any cause 26.3 20.8 0.08
From cardiovascular cause 7.6 9.0 0.52
Repeat hospitalization 23.9 18.2 0.05
Mortality or repeat
hospitalization
42.0 32.6 0.007
Stroke 3.5 5.8 0.27
Myocardial infarction* 2.1 1.8 0.97
Values are %. *Excludes periprocedural myocardial infarction.
PPM ¼ permanent pacemaker.
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65endpoints and core laboratory interpretation of ECGs
and echocardiograms. The principal ﬁndings are that:
1) new PPM within 30 days of TAVR with ESV was
required in 8.8% of patients without prior pacemaker;
2) by multivariable analysis, independent predictors
of new PPM included baseline RBBB, larger prosthesis
to LVOT diameter ratio, smaller LVEDd, and treat-
ment in the continued access registry; 3) new PPM
was associated with a longer duration of hospitaliza-
tion after TAVR and signiﬁcantly higher rates of
repeat hospitalization and mortality or repeat hospi-
talization at 1 year; and 4) at 1 year, new PPM was not
associated with signiﬁcant differences in LVEF.
Cardiac conduction disturbances occur frequently
after both surgical and transcatheter aortic valve
replacement and may require PPM. This is likely due
to both the high prevalence of comorbid conduction
system disease in patients with AS and the close
anatomic proximity of the infranodal conduction
system to the aortic valvular complex (7,8). Mecha-
nisms of conduction system injury have been shown
to include direct trauma, compression, hemorrhage,
and ischemia or infarction of the conduction system
tissues (9–11). In recent series, the incidence of PPM
after isolated surgical aortic valve replacement for AS
has ranged from 3.2% to 7.1% (2,12–14). The require-
ment for PPM after TAVR with ESV is similar, with
average rates ranging from 5.9% to 6.5% in large
meta-analyses (3–5). The rate of new PPM of 8.8%
among patients without prior pacemakers in the
current study is well within the previously-reported
range for ESV. Reported PPM rates with MCV are
substantially higher, ranging from 24.5% to 25.8% in
the meta-analyses (3–5). Similarly, in the recently
reported CoreValve High Risk and Extreme Risk Tri-
als, the new pacemaker rates were 19.8% and 21.6%,
respectively, overall, or approximately 25% and 29%
among patients without pre-existing pacemakers
(15,16). The higher rate of new PPM with MCV is likely
due to differences in stent design and properties
(self-expanding vs. balloon-expandable) that inﬂu-
ence the position of the valve frame within the
LVOT and the radial force exerted on the conduction
system (17).
PPM TIMING AND INDICATION. Limited data are
available regarding PPM type, timing, and indication
after TAVR, particularly with respect to ESV. In the
current analysis, the majority of PPM were either
single- or dual-chamber right ventricular pacemakers
(>95%) implanted within a week of TAVR (86%) and
during index hospitalization (97%). The indication for
PPM was high-degree atrioventricular block in
approximately 80% of cases. This correlates well with
FIGURE 3 1-Year Clinical Outcomes
Kaplan-Meier curves are displayed for 1-year clinical outcomes, including: (A) death, (B)
cardiovascular death, (C) repeat hospitalization, and (D) death or repeat hospitalization.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
Continued on the next page
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66a recent, smaller series, in which 82% of PPM after
ESV were implanted within 1 week, and the indication
was high-degree atrioventricular block in 75% (18).
Interestingly, in the current analysis, the indication
for PPM was sick sinus syndrome in more than 17%,
which is higher than previously reported. Further-
more, the rate of PPM was higher in the continued
access registry than the randomized trial (9.6% vs.
5.6%), and the association persisted after adjustment
for differences in baseline characteristics. This sug-
gests that differing physician thresholds for PPM mayplay an important role in PPM rates after TAVR,
particularly outside the rigorous conﬁnes of a ran-
domized trial.
Although the available data in this study did not
permit deﬁnitive analysis of long-term pacemaker
dependency, a review of the ECGs showed a paced
rhythm in only approximately 50% of patients at each
time point. This correlates with prior studies, pre-
dominantly including MCV, showing long-term
pacemaker dependency rates <50% after TAVR
(19–21). Given these considerations, recent studies
have investigated the safety of more conservative
strategies of PPM after TAVR (22). Further research is
required to predict pacemaker dependency and to
clarify the optimal PPM indications after TAVR.
PREDICTORS OF PPM. The largest prior analysis of
predictors of PPM after TAVR, from a German regis-
try, identiﬁed the use of MCV, porcelain aorta, and
lack of prior valve surgery as predictors of PPM (23).
Although the study included both MCV (n ¼ 912) and
ESV (n ¼ 232), >90% of the PPM events were after
MCV. With respect to ESV alone, the largest study is a
Canadian registry of 411 patients without prior pace-
maker that identiﬁed baseline RBBB as the only pre-
dictor of PPM (24). A number of other small registry
studies have consistently identiﬁed MCV (as opposed
to ESV) and baseline RBBB as predictors of PPM (3,25).
Beyond these, the studies have variously identiﬁed
an array of ECG, imaging, and procedural risk factors
for PPM. Notable among these are the depth of im-
plantation below the aortic valve annulus and the
degree of calciﬁcation of the aortic annulus, mitral
annulus, LVOT, or aorta (3,8,22,25–28). Important
limitations of these studies include their small size
and lack of core laboratory and CEC adjudication.
The current, large study with ESV conﬁrms base-
line RBBB as an important predictor of PPM and
identiﬁes prosthesis to LVOT diameter ratio and
LVEDd as novel predictors of PPM. A prior, small
study of MCV identiﬁed LVOT diameter as a predic-
tor, but did not analyze the prosthesis to LVOT
diameter ratio (29). In the current study, LVOT
diameter was associated with PPM by univariate
analysis, but only the prosthesis to LVOT diameter
ratio was an independent predictor of PPM by multi-
variable analysis. Like implantation depth, this ratio
is intuitively appealing as a potential marker of
increased risk for injury to the conduction system as
it courses through the septum near the LVOT. This
may be particularly important in the setting of a
“septal bulge,” which can result in a smaller LVOT
measurement and increased prosthesis to LVOT
diameter ratio. It is important to note that
FIGURE 3 Continued
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67implantation depth and calciﬁcation data were not
available in the present analysis. Further study is
necessary to assess the interplay of these various
anatomic and procedural factors in causing conduc-
tion abnormalities after TAVR.
CLINICAL IMPLICATIONS OF PPM. Isolated right
ventricular apical pacing is not benign in patients
with structural heart disease and has been associated
with repeat hospitalization and mortality (30–32).
However, few studies have investigated the effect of
PPM after TAVR on clinical outcomes. A recent, large,
mixed series of 1,556 TAVR recipients (ESV 858, MCV
698) showed no association of new PPM after TAVR
with long-term mortality and mortality or repeat
hospitalization (18). The other large series of 1,147
TAVR patients from the German registry showed no
association of new PPM with 30-day mortality, but
did not examine long-term outcomes (23). Two
smaller series, predominantly with MCV, demon-
strated no effect of PPM on 1-year all-cause mortality
(22,33). The current analysis, representing the largest
reported experience, showed no clear association
of PPM after TAVR with 1-year mortality, but did
demonstrate an association of new PPM with
increased duration of hospitalization and increased
rehospitalization and hospitalization or mortality af-
ter TAVR. The economic effect of the additional pro-
cedure, longer hospitalization, and rehospitalization
must be considered given the current health care
environment.
Ventricular conduction delays have been shown to
have a negative effect on LV function in heart failure
patients that may be successfully treated with cardiac
resynchronization therapy (34,35). Isolated right
ventricular pacing, which mimics left bundle branch
block, has also been shown to negatively affect LV
function (31,36). Several recent studies have shown
that conduction disturbances, including both LBBB
and PPM, after TAVR may negatively affect subse-
quent recovery of LVEF (18,37–39). However, the
current analysis failed to show an effect of new PPM
on LVEF recovery. There are several potential expla-
nations for this, including fewer patients with base-
line depressed LVEF in this cohort, the incomplete
rate of long-term pacemaker dependency, and im-
plantation of biventricular pacemakers in rare cases.
It is worth noting that recent case reports have
described success with cardiac resynchronization
therapy after TAVR in patients with conduction dis-
turbances, LV dysfunction, and persistent symptoms
(40,41). Further studies of PPM after TAVR, particu-
larly focusing on pacemaker-dependent patients and
those with depressed LVEF, will be necessary todetermine the effect of PPM on LVEF recovery and
potential indications for biventricular pacing.
STUDY LIMITATIONS. This report consists of a retro-
spective analysis of existing data and is subject to all
of the limitations inherent in this study design. A
limitation of this analysis is that certain previously
identiﬁed predictors of PPM after TAVR, such as
depth of valve implantation and calciﬁcation, are not
available in this dataset. Data on medications that
could affect cardiac conduction are also not available.
Another limitation is that comprehensive analysis of
pacemaker dependency was not possible from the
data, but was estimated from ECGs to be approxi-
mately 50% at each time point. To the extent that
pacemaker dependency was incomplete, the clinical
FIGURE 4 Evolution of Left Ventricular Function
The change in left ventricular ejection fraction over time is shown, stratiﬁed by permanent
pacemaker.
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68effect of long-term right ventricular apical pacing
may be underestimated. Finally, LV function was
relatively preserved in this cohort (mean LVEF
>50%), so a disproportionate effect of PPM in patients
with depressed LV function cannot be ruled out.CONCLUSIONS
Among patients who underwent TAVR with a
balloon-expandable valve in the PARTNER trial
and registry, PPM was required within 30 days in
8.8% of patients without a prior pacemaker. Inde-
pendent predictors of new PPM included RBBB,
prosthesis to LVOT diameter ratio, smaller LVEDd,
and treatment in the continued access registry. New
PPM was associated with signiﬁcantly longer post-
procedure hospitalization and increased repeat
hospitalization and mortality or repeat hospitali-
zation at 1 year. PPM did not adversely affect
the recovery of LVEF after TAVR, although pace-
maker dependency was only approximately 50% at
follow-up.
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